Simulations Plus Joins European SimInhale Consortium

Keywords: European Cooperation in Science and Technology, formulation design, inhaled medicines, lung tissue, particle aerosolization, pulmonary model, pulmonary playlist, SimInhale, toxicity analysis
Division: Simulations Plus

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of modeling and simulation software for pharmaceutical discovery and development, today announced that it has been accepted into the SimInhale COST (European Cooperation in Science and Technology) Action, a consortium composed of approximately 100 current university, research institute, and industry members from across Europe.

As one of only two U.S. participants, Simulations Plus will participate in activities designed to:

  • advance particle designs for improved deposition and interaction with lung tissue
  • promote realistic computer simulations of particle aerosolization, delivery and deposition
  • promote patient-tailored inhaled medicines
  • promote integration of device and formulation design
  • promote critical assessment of toxicity issues and related risks

SimInhale will establish a roadmap to realistic computer simulations that will provide quantitative data to designers of aerosolized medicines and inhalation devices. Simulations Plus was invited to join SimInhale because of its state-of-the-art Pulmonary Compartmental Absorption and Transit (PCAT™) Module in its industry-leading GastroPlus™ physiologically based pharmacokinetics (PBPK) software program. Simulations Plus scientists will participate in several Working Groups within SimInhale.

John DiBella, vice president for marketing and sales for Simulations Plus, said, “Our acceptance into this prestigious group validates our expertise with aerosolization, and gives us the opportunity to work directly with the outstanding members of SimInhale for the advancement of simulation technology for inhaled medicines. We will participate as full members with access to data and expertise that will help us to improve our pulmonary model to better serve industry, regulatory agencies, and academia in this important area.”